- Home
- VOYA vs MIRM Comparison
VOYA vs MIRM Comparison
Compare VOYA & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VOYA | MIRM |
|---|---|---|
| Founded | 1975 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Life Insurance | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.3B | 7.2B |
| IPO Year | 2012 | 2019 |
Fundamental Metrics
Financial Performance| Metric | VOYA | MIRM |
|---|---|---|
| Price | $94.48 | $84.02 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 14 |
| Target Price | $108.08 | ★ $138.21 |
| AVG Volume (30 Days) | ★ 844.6K | 547.3K |
| Earning Date | 11-03-2026 | 11-03-2026 |
| Dividend Yield | ★ 1.99% | N/A |
| EPS Growth | 1.94 | ★ 74.59 |
| EPS | ★ 2.73 | N/A |
| Revenue | ★ $8,189,000,000.00 | $19,138,000.00 |
| Revenue This Year | N/A | $33.62 |
| Revenue Next Year | $4.94 | $17.65 |
| P/E Ratio | $34.89 | ★ N/A |
| Revenue Growth | ★ 1.73 | N/A |
| 52 Week Low | $64.50 | $63.23 |
| 52 Week High | $105.64 | $130.00 |
Technical Indicators
Market Signals| Indicator | VOYA | MIRM |
|---|---|---|
| Relative Strength Index (RSI) | 31.81 | 31.00 |
| Support Level | $88.51 | $73.82 |
| Resistance Level | $104.18 | $98.03 |
| Average True Range (ATR) | 2.51 | 3.81 |
| MACD | -0.85 | -0.62 |
| Stochastic Oscillator | 13.17 | 9.26 |
Price Performance
Historical ComparisonAbout VOYA Voya Financial Inc.
Voya Financial Inc is a financial services company, which, through its subsidiaries, provides various investment, insurance, and retirement solutions to individual and institutional clients in the United States. Its products and services include tax savings plans, individual retirement accounts, group life insurance plans, and employee benefits products, among others. The company tailors each of its products to the needs of its customer base. It operates its business through three principal lines: Retirement, Investment Management and Employee Benefits.The majority revenue is from Retirement segment.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.